title: Novel agents for muscle-invasive and advanced urothelial cancer.
abstract: Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced urothelial cancer. Salvage therapy is an unmet need, with disappointing outcomes. The profusion of novel biological agents offers the promise of improved outcomes. Neoadjuvant therapy before cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.
authors.affiliation: US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA. guru.sonpavde@usoncology.com
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Robert
authors.initials: R
authors.lastname: Ross
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Sweeney
authors.forename: Noah
authors.initials: N
authors.lastname: Hahn
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Hutson
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.forename: Seth P
authors.initials: SP
authors.lastname: Lerner
authors.forename: Cora N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000188:drug therapy; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology